Panacea Biotec Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Panacea Biotec Ltd. on BSE

Load latest

Panacea Biotec Ltd.

24 May 2025

407.55

-2.69%

Board Meeting

Panacea Biotec Ltd - 531349 - Board Meeting Intimation for For Approval Of The Audited Financial …

BSE India

Panacea Biotec Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31, 2025 and passing over of dividend on equity as well as preference shares for the said Financial Year

pdf

Panacea Biotec Ltd.

19 May 2025

407.55

-2.69%

Company Update

Panacea Biotec Ltd - 531349 - Nation-Wide Study Undertaken By Panacea Biotec Pharma Ltd. (Material WOS) …

BSE India

A copy of the Nation-Wide Study undertaken by Panacea Biotec Pharma Ltd. (material WOS) confirms ChilRun full Accelerates Growth and Development in Children, in just 90 days, is enclosed herewith.

pdf

Panacea Biotec Ltd.

06 May 2025

407.55

-2.69%

Company Update

Panacea Biotec Ltd - 531349 - Details Of Shares Dematerialized During April 2025 Under Regulation 74(5) …

BSE India

Please find attached details of shares dematerialised during April, 2025 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018

pdf

Panacea Biotec Ltd.

29 Apr 2025

407.55

-2.69%

Corp. Note

Panacea Biotec Ltd - 531349 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyPanacea Biotec Ltd 2CIN NO.L33117PB1984PLC022350 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 15.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Vinod Goel Designation: Group CFO and Head Legal and Company Secretary EmailId: vinodgoel@panaceabiotec.com Name of the Chief Financial Officer: Devender Gupta Designation: CFO and Head Information Technology EmailId: devendergupta@panaceabiotec.com Date: 29/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Panacea Biotec Ltd.

23 Apr 2025

407.55

-2.69%

Company Update

Panacea Biotec Ltd - 531349 - Receipt Of An Additional Award From UNICEF For Supply Of …

BSE India

We are delighted to inform you that Panacea Biotec Ltd. has received an additional Award from UNICEF for supply of 40 million doses of its bivalent oral polio vaccine (bOPV) worth ~US$ 5.20 million (~Rs.44 Crore) in Q3 CY2025. The details with respect to the said Award in the specified format as per the SEBI Circular dated July 13, 2023, is annexed herewith.

pdf

Panacea Biotec Ltd.

07 Apr 2025

407.55

-2.69%

Company Update

Panacea Biotec Ltd - 531349 - Details Of Shares Dematerialized During March 2025

BSE India

This is to inform that no share has been dematerialised during the month March 2025. A copy of certificate obtained from the Company''s RTA regarding number of shares dematerialised as on 31.03.2025 is enclosed herewith.

pdf

Panacea Biotec Ltd.

03 Apr 2025

407.55

-2.69%

Company Update

Panacea Biotec Ltd - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

We are enclosing herewith a certificate dated April 02, 2025, issued by Skyline Financial Services Private Limited, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2025.

pdf

Panacea Biotec Ltd.

01 Apr 2025

407.55

-2.69%

Company Update

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

We would like to inform you that Mr. Sunil Anand, Associate Director - Finance & Corporate Affairs of the Company, designated as Senior Management Personnel, has superannuated from the services of the Company on March 31, 2025. Consequently, he ceased to be Senior Management Personnel of the Company on March 31, 2025.

pdf

Panacea Biotec Ltd.

01 Apr 2025

407.55

-2.69%

Company Update

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Change in Directorate

BSE India

We would like to inform you that Mr. Narotam Kumar Juneja, non-executive non independent director of the Company was re-appointed as director liable to retire by rotation in the AGM held on 27.09.2024, for a period upto 31.03.2025. Accordingly, he has completed his tenure as non-executive non-independent director and consequently ceased to be director of the Company on 31.03.2025. Similarly, he has also completed his tenure as Whole-time Director in the Company''s material subsidiary, Panacea Biotec Pharma Ltd. on 31.03.2025. The details as required under SEBI Circular dated 13.07.2023 are attached herewith.

pdf

Panacea Biotec Ltd.

31 Mar 2025

407.55

-2.69%

AGM

Panacea Biotec Ltd - 531349 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

BSE India

We would like to inform you that as per the Scrutinizer''s Report, all the resolutions mentioned in the Postal ballot notice dated February 14, 2025 have been passed by the shareholders with requisite majority. The detailed voting results along with the Scrutinizer''s Report are attached herewith.

pdf

Is Panacea Biotec Ltd. worth buying?

219 Votes:

Buy 77.17%

Sell 13.24%

Hold 9.59%